Exagen (NASDAQ:XGN) Stock: Insider Jorey Chernett Sells 109,436 Shares

Exagen Inc. (NASDAQ:XGN – Get Free Report) major shareholder Jorey Chernett sold 109,436 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $4.65, for a total value of $508,877.40. Following the transaction, the insider directly owned 2,587,504 shares in the company, valued at approximately $12,031,893.60. This represents a 4.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Jorey Chernett also recently made the following trade(s):

  • On Friday, November 13th, Jorey Chernett sold 58,068 shares of Exagen stock. The stock was sold at an average price of $4.08, for a total value of $236,917.44.
  • On Wednesday, November 11th, Jorey Chernett purchased 71,315 shares of Exagen stock. The stock was bought at an average price of $5.23 per share, with a total value of $372,977.45.
  • On Friday, November 6th, Jorey Chernett sold 11,265 shares of Exagen stock. The stock was sold at an average price of $6.14, for a total transaction of $69,167.10.
  • On Tuesday, November 10th, Jorey Chernett acquired 7,085 shares of Exagen stock. The shares were purchased at an average price of $5.26 per share, for a total transaction of $37,267.10.
  • On Monday, November 9th, Jorey Chernett acquired 8,500 shares of Exagen stock. The shares were purchased at an average price of $6.35 per share, for a total transaction of $53,975.00.
  • On Monday, October 19th, Jorey Chernett bought 14,000 shares of Exagen stock. The stock was purchased at an average cost of $7.46 per share, for a total transaction of $104,440.00.

Exagen Trading Down 6.3%

Shares of XGN traded down $0.28 during midday trading on Friday, hitting $4.13. The stock had a trading volume of 3,356,140 shares, compared to its average volume of 581,895. The stock’s 50 day moving average is $7.71 and its 200 day moving average is $5.13. The firm has a market cap of $105.36 million, a PE ratio of -5.51 and a beta of 2.25. The company has a debt-to-equity ratio of 1.73, a current ratio of 3.46 and a quick ratio of 3.18. Exagen Inc. has a 1 year low of $2.59 and a 1 year high of $9.28.

Exagen (NASDAQ:XGN – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). The firm had revenue of $18.42 million for the quarter, compared to analysts’ expectations of $18.34 million. Exagen had a negative return on equity of 125.60% and a negative net margin of 25.14%. As a group, analysts forecast that Exagen Inc. will post -0.71 EPS for the current fiscal year.

Trending Headlines about Exagen

These are some of the XGN headlines that stood out recently:

  • Positive Sentiment: Exagen’s earnings call highlighted growth and expansion of its testing platform, which could support its longer-term business prospects. Article: Exagen Earnings Call Highlights Growth and Platform Expansion
  • Positive Sentiment: KeyCorp forecasts a smaller per-share loss in 2027 than in 2026, while Canaccord and BTIG maintain Buy ratings. Canaccord’s reduced $9 target is still above the recent share price; analysts’ average target is reported at $9.88.
  • Negative Sentiment: Major shareholder Jorey Chernett’s recent transactions were net selling: sales of about 178,800 shares outweighed purchases of about 100,900 shares. The sales may concern investors, although Chernett retained a substantial stake. Article: Exagen Stock: Insider Jorey Chernett Sells 109,436 Shares

Analyst Upgrades and Downgrades

XGN has been the topic of several recent analyst reports. Canaccord Genuity Group reduced their price target on Exagen from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday. B. Riley Financial assumed coverage on Exagen in a research note on Friday, September 11th. They set a “buy” rating and a $12.00 price target for the company. TD Cowen boosted their price objective on Exagen from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. BTIG Research reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Exagen in a research report on Wednesday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Exagen in a research note on Wednesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Exagen has an average rating of “Moderate Buy” and a consensus price target of $9.88.

View Our Latest Analysis on Exagen

Hedge Funds Weigh In On Exagen

A number of hedge funds have recently added to or reduced their stakes in XGN. Jump Financial LLC increased its position in shares of Exagen by 596.9% during the third quarter. Jump Financial LLC now owns 81,714 shares of the company’s stock worth $664,000 after acquiring an additional 69,989 shares during the period. Flputnam Investment Management Co. grew its stake in Exagen by 3.8% in the third quarter. Flputnam Investment Management Co. now owns 299,828 shares of the company’s stock worth $2,438,000 after purchasing an additional 11,018 shares in the last quarter. Marshall Wace LLP increased its holdings in Exagen by 28.1% during the 3rd quarter. Marshall Wace LLP now owns 392,789 shares of the company’s stock worth $3,193,000 after purchasing an additional 86,086 shares during the period. Empowered Funds LLC purchased a new position in Exagen during the 3rd quarter worth $198,000. Finally, Russell Investments Group Ltd. purchased a new position in Exagen during the 3rd quarter worth $418,000. 75.25% of the stock is currently owned by institutional investors.

About Exagen

(Get Free Report)

Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.

Recommended Stories

Insider Buying and Selling by Quarter for Exagen (NASDAQ:XGN)

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.